… The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, …
for treatment of the majority of patients with venous thromboembolism (VTE). With a rapid onset …

Introduction Acute venous thromboembolism (VTE) is a common disease associated to
significant morbidity and mortality. Materials and methods We systematically reviewed and meta-…

… anticoagulation intensity. Over the past decade, the introduction of new oral anticoagulants
that … In this Review, we outline the use of the novel oral anticoagulants apixaban, dabigatran, …

… on new oral anticoagulants for … oral anticoagulants”, “direct oral anticoagulants”, “apixaban”,
“dabigatran”, “edoxaban”, “rivaroxaban”, “venous thromboembolism”, “deep vein thrombosis…

… anticoagulant therapy is effective when compared with the newer direct oral anticoagulants
(… Heparin and its derivatives must be administered parenterally, whereas use of oral vitamin K …

… the gold standard of anticoagulation for VTE. Recently, direct oral anticoagulants (DOACs)
that … and dose adjustment have revolutionized anticoagulation management in VTE. Here, we …

… trials have shown that direct oral anticoagulants (DOACs) are a safe and effective
alternative to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). …

… For recurrent acute venous thromboembolism, we found no evidence of difference between
any of the novel oral anticoagulants and the vitamin K antagonists for each comparison (fig 2…

… The direct oral anticoagulants (DOACs) represent a major advance in oral anticoagulant …
By simplifying long-term anticoagulant therapy and improving its safety, the DOACs have …

… Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer
and acute venous thromboembolism (VTE), but studies have reported inconsistent results. …